Latest Insider Transactions at Bio Techne Corp (TECH)
This section provides a real-time view of insider transactions for Bio Techne Corp (TECH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIO-TECHNE Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIO-TECHNE Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 01
2024
|
James Hippel CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,475
-5.73%
|
$485,625
$75.31 P/Share
|
|
Nov 01
2024
|
James Hippel CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,159
+10.42%
|
-
|
|
Nov 01
2024
|
Kim Kelderman Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,430
-5.86%
|
$182,250
$75.31 P/Share
|
|
Nov 01
2024
|
William Geist PRESIDENT, PROTEIN SCIENCES |
SELL
Payment of exercise price or tax liability
|
Direct |
3,270
-22.79%
|
$245,250
$75.31 P/Share
|
|
Nov 01
2024
|
William Geist PRESIDENT, PROTEIN SCIENCES |
BUY
Exercise of conversion of derivative security
|
Direct |
9,912
+40.85%
|
-
|
|
Oct 24
2024
|
Robert V Baumgartner Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,462
+3.16%
|
-
|
|
Oct 24
2024
|
Judith V Klimovsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,462
+40.57%
|
-
|
|
Oct 24
2024
|
Alpna Seth Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,462
+9.6%
|
-
|
|
Oct 24
2024
|
Roeland Nusse Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,462
+3.18%
|
-
|
|
Oct 24
2024
|
John L Higgins Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,462
+2.94%
|
-
|
|
Oct 24
2024
|
Julie L Bushman Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,462
+17.01%
|
-
|
|
Oct 24
2024
|
Rupert Vessey Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,462
+13.53%
|
-
|
|
Oct 24
2024
|
Joseph D Keegan Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,462
+9.6%
|
-
|
|
Sep 12
2024
|
John L Higgins Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,874
-3.86%
|
$136,802
$73.2 P/Share
|
|
Sep 12
2024
|
John L Higgins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+10.99%
|
$132,000
$22.95 P/Share
|
|
Aug 29
2024
|
Kim Kelderman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,492
+3.48%
|
$98,472
$66.97 P/Share
|
|
Aug 15
2024
|
Shane Bohnen SVP - General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
15
-0.88%
|
$1,110
$74.91 P/Share
|
|
Aug 15
2024
|
Shane Bohnen SVP - General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
49
+2.81%
|
-
|
|
Aug 08
2024
|
Robert V Baumgartner Director |
SELL
Open market or private sale
|
Direct |
16,000
-26.94%
|
$1,152,000
$72.1 P/Share
|
|
Aug 08
2024
|
Robert V Baumgartner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+21.22%
|
$352,000
$22.95 P/Share
|
|
Aug 02
2024
|
James Hippel CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
36,076
-26.53%
|
$2,958,232
$82.35 P/Share
|
|
Aug 02
2024
|
James Hippel CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
53,000
+28.04%
|
$1,643,000
$31.26 P/Share
|
|
Jul 31
2024
|
Kim Kelderman Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,479
-19.18%
|
$767,799
$81.97 P/Share
|
|
Jul 31
2024
|
Kim Kelderman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,000
+22.07%
|
$518,000
$37.7 P/Share
|
|
Jul 23
2024
|
James Hippel CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
24,282
-22.63%
|
$1,869,714
$77.77 P/Share
|
|
Jul 23
2024
|
James Hippel CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+24.6%
|
$1,085,000
$31.26 P/Share
|
|
Jul 08
2024
|
John L Higgins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+12.34%
|
$132,000
$22.95 P/Share
|
|
May 14
2024
|
John L Higgins Director |
SELL
Open market or private sale
|
Direct |
4,000
-9.85%
|
$332,000
$83.84 P/Share
|
|
May 14
2024
|
John L Higgins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+8.97%
|
$88,000
$22.95 P/Share
|
|
May 01
2024
|
Judith V Klimovsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
680
+50.0%
|
-
|
|
Apr 03
2024
|
Shane Bohnen SVP - General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
747
-31.2%
|
$50,049
$67.87 P/Share
|
|
Apr 03
2024
|
Shane Bohnen SVP - General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,259
+48.55%
|
-
|
|
Mar 07
2024
|
Roeland Nusse Director |
SELL
Open market or private sale
|
Direct |
10,400
-19.44%
|
$790,400
$76.98 P/Share
|
|
Feb 01
2024
|
William Geist PRESIDENT, PROTEIN SCIENCES |
SELL
Payment of exercise price or tax liability
|
Direct |
1,111
-12.53%
|
$75,548
$68.54 P/Share
|
|
Dec 19
2023
|
James Hippel CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
32,966
-31.44%
|
$2,538,382
$77.42 P/Share
|
|
Dec 19
2023
|
James Hippel CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
47,289
+31.08%
|
$1,465,959
$31.26 P/Share
|
|
Nov 01
2023
|
Kim Kelderman Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,196
+28.61%
|
-
|
|
Oct 26
2023
|
Alpna Seth Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,625
+11.66%
|
-
|
|
Oct 26
2023
|
Rupert Vessey Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,625
+17.09%
|
-
|
|
Oct 26
2023
|
Julie L Bushman Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,625
+22.27%
|
-
|
|
Oct 26
2023
|
John L Higgins Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,625
+4.25%
|
-
|
|
Oct 26
2023
|
Randolph C Steer Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,625
+6.29%
|
-
|
|
Oct 26
2023
|
Roeland Nusse Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,625
+2.95%
|
-
|
|
Oct 26
2023
|
Joseph D Keegan Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,625
+11.66%
|
-
|
|
Oct 26
2023
|
Robert V Baumgartner Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,625
+3.61%
|
-
|
|
Aug 30
2023
|
Roeland Nusse Director |
SELL
Open market or private sale
|
Direct |
8,939
-14.7%
|
$715,120
$80.32 P/Share
|
|
Aug 30
2023
|
Roeland Nusse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
32,000
+23.57%
|
$704,000
$22.4 P/Share
|
|
Aug 24
2023
|
Kim Kelderman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,100
+9.0%
|
$98,700
$47.6 P/Share
|
|
Aug 15
2023
|
Charles R. Kummeth Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,675
-0.67%
|
$728,700
$84.61 P/Share
|
|
Aug 15
2023
|
Charles R. Kummeth Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,632
+1.35%
|
-
|